The Hindu Business Line : Sunday, January 01, 2006

Investors had much to cheer in 2005
It's a Sensex story all the way; large-caps made a big come-back
WHAT a year it was! Just when investors had established a level of comfort with the Sensex at the 6,500-point level, the index once again proved its ability to pull off a surprise by closing out 2005 well past the 9,000-mark. Indeed, 2005 may ... More

SEBI goes easy on takeover norms — Promoters allowed to have higher stake
THE Securities and Exchange Board of India (SEBI) amendment to the takeover regulations has given more flexibility to promoters for hiking their stakes from 55 per cent to 75 per cent and beyond, in a move to help companies that go for corporate ... More

Cos rush to comply with Clause 49
AS the last day for complying with Clause 49 for appointing independent directors ends on Saturday, several companies called for their board meeting to meet with the SEBI requirement. Notice with stock exchanges said that several companies, ... More

Surcharge, tax can make you pay more for flying cheap — It will pay to read the fine print
Airlines officials said that they have to incur costs that vary and hence they have little choice but to levy surcharge More

`Investors need not be deterred by zooming Sensex'
THE zooming Sensex is not a deterrent for investing in capital markets but it is important that investors keep in mind what they are buying, how much they are investing, why they are buying, and when are they going to sell, according to Mr R. ... More

CEOs of 15 Fortune-100 firms were here in 2005 — Buoyancy in manufacturing, services attracting attention
LOOK, who came calling on us in 2005. Chiefs of five of the ten companies that head the Fortune-500 list made India their stopover destination. So did another 15 from the Fortune-100 list make a strategic visit here, going to show that India ... More

Pharma: Some agony, not much ecstasy
IF the domestic pharmaceutical industry will remember the year 2005 as the watershed year of the patent regime and sightings of growth opportunities, it will also not forget the other heartburns that came along. The much awaited pharma policy is ... More